Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.
Nutriband (NASDAQ: NTRB) has secured a Certificate of Registration from the USPTO for trademark registration Number 7,692,920 on February 18, 2025. The trademark covers product research and development, scientific research and development, biochemical research and development, and pharmaceutical research and development under Class 042.
The Nutriband™ trademark is important for commercializing the company's AVERSA platform technology, designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential in transdermal patches. The company's leading product, AVERSA™ Fentanyl, is being developed in partnership with Kindeva Drug Delivery, focusing on scaling up commercial manufacturing before FDA submission. Market analysis by Health Advances projects potential peak annual U.S. sales of $80-200 million for AVERSA™ Fentanyl.
Nutriband (NASDAQ: NTRB) ha ottenuto un Certificato di Registrazione dall'USPTO per la registrazione del marchio Numero 7.692.920 il 18 febbraio 2025. Il marchio copre la ricerca e lo sviluppo di prodotti, la ricerca scientifica e lo sviluppo, la ricerca e lo sviluppo biochimico e la ricerca e lo sviluppo farmaceutico sotto la Classe 042.
Il marchio Nutriband™ è importante per la commercializzazione della tecnologia della piattaforma AVERSA dell'azienda, progettata per prevenire abusi, deviazioni, usi impropri e esposizione accidentale a farmaci con potenziale di abuso nei cerotti transdermici. Il prodotto di punta dell'azienda, AVERSA™ Fentanyl, è in fase di sviluppo in collaborazione con Kindeva Drug Delivery, concentrandosi sull'aumento della produzione commerciale prima della presentazione all'FDA. L'analisi di mercato condotta da Health Advances prevede vendite annuali potenziali negli Stati Uniti di $80-200 milioni per AVERSA™ Fentanyl.
Nutriband (NASDAQ: NTRB) ha obtenido un Certificado de Registro de la USPTO para la inscripción de la marca Número 7.692.920 el 18 de febrero de 2025. La marca cubre la investigación y el desarrollo de productos, la investigación científica y el desarrollo, la investigación bioquímica y el desarrollo, y la investigación y el desarrollo farmacéutico bajo la Clase 042.
La marca Nutriband™ es importante para la comercialización de la tecnología de la plataforma AVERSA de la empresa, diseñada para prevenir el abuso, la desviación, el mal uso y la exposición accidental a medicamentos con potencial de abuso en parches transdérmicos. El producto principal de la empresa, AVERSA™ Fentanyl, se está desarrollando en colaboración con Kindeva Drug Delivery, centrándose en aumentar la fabricación comercial antes de la presentación a la FDA. El análisis de mercado realizado por Health Advances proyecta ventas anuales potenciales en EE. UU. de $80-200 millones para AVERSA™ Fentanyl.
Nutriband (NASDAQ: NTRB)는 2025년 2월 18일 USPTO로부터 상표 등록 번호 7,692,920에 대한 등록 증명서를 확보했습니다. 이 상표는 제품 연구 및 개발, 과학 연구 및 개발, 생화학 연구 및 개발, 제약 연구 및 개발을 클래스 042로 포함합니다.
Nutriband™ 상표는 약물 남용 가능성을 가진 약물의 남용, 유용, 오용 및 우발적 노출을 방지하기 위해 설계된 회사의 AVERSA 플랫폼 기술을 상용화하는 데 중요합니다. 회사의 주요 제품인 AVERSA™ Fentanyl은 Kindeva Drug Delivery와 협력하여 개발 중이며, FDA 제출 전에 상업적 제조를 확대하는 데 집중하고 있습니다. Health Advances의 시장 분석에 따르면 AVERSA™ Fentanyl의 미국 내 잠재적 연간 판매는 8천만에서 2억 달러에 이를 것으로 예상됩니다.
Nutriband (NASDAQ: NTRB) a obtenu un Certificat d'Enregistrement de l'USPTO pour le numéro d'enregistrement de marque 7.692.920 le 18 février 2025. La marque couvre la recherche et le développement de produits, la recherche scientifique et le développement, la recherche et le développement biochimique, ainsi que la recherche et le développement pharmaceutique sous la Classe 042.
La marque Nutriband™ est importante pour la commercialisation de la technologie de plateforme AVERSA de l'entreprise, conçue pour prévenir l'abus, la déviation, l'utilisation abusive et l'exposition accidentelle à des médicaments ayant un potentiel d'abus dans des patchs transdermiques. Le produit phare de l'entreprise, AVERSA™ Fentanyl, est en cours de développement en partenariat avec Kindeva Drug Delivery, en se concentrant sur l'augmentation de la fabrication commerciale avant la soumission à la FDA. L'analyse de marché par Health Advances prévoit des ventes annuelles potentielles aux États-Unis de 80 à 200 millions de dollars pour AVERSA™ Fentanyl.
Nutriband (NASDAQ: NTRB) hat am 18. Februar 2025 ein Registrierungszertifikat von der USPTO für die Markenregistrierungsnummer 7.692.920 erhalten. Die Marke umfasst Produktforschung und -entwicklung, wissenschaftliche Forschung und Entwicklung, biochemische Forschung und Entwicklung sowie pharmazeutische Forschung und Entwicklung unter Klasse 042.
Die Marke Nutriband™ ist wichtig für die Kommerzialisierung der Plattformtechnologie AVERSA des Unternehmens, die darauf abzielt, Missbrauch, Abweichung, Missbrauch und versehentliche Exposition gegenüber Arzneimitteln mit Missbrauchspotenzial in transdermalen Pflastern zu verhindern. Das führende Produkt des Unternehmens, AVERSA™ Fentanyl, wird in Zusammenarbeit mit Kindeva Drug Delivery entwickelt und konzentriert sich darauf, die kommerzielle Herstellung vor der FDA-Einreichung hochzufahren. Marktanalysen von Health Advances prognostizieren potenzielle jährliche Verkaufszahlen in den USA von 80 bis 200 Millionen US-Dollar für AVERSA™ Fentanyl.
- Secured USPTO trademark registration for pharmaceutical R&D
- Partnership with Kindeva Drug Delivery for commercial manufacturing scale-up
- Projected peak annual U.S. sales potential of $80-200 million for AVERSA Fentanyl
- None.
Insights
The USPTO trademark registration represents a important intellectual property milestone for Nutriband, extending beyond mere branding to encompass comprehensive protection for their pharmaceutical research and development activities. This strategic move significantly strengthens their market position in the $8.7 billion transdermal drug delivery sector.
The trademark's scope, covering scientific and biochemical R&D, is particularly valuable for their AVERSA technology platform. This IP protection creates a robust foundation for commercializing their abuse-deterrent transdermal system, especially critical given the sensitive nature of fentanyl products. The partnership with Kindeva Drug Delivery, a respected player in drug delivery technologies, adds substantial credibility to their manufacturing capabilities and potential market access.
The projected peak annual U.S. sales of
The timing of this trademark registration aligns strategically with their manufacturing scale-up efforts, potentially accelerating their path to FDA submission. This IP protection could also facilitate future licensing opportunities or partnerships, providing additional revenue streams beyond direct product sales. However, investors should note that success ultimately depends on FDA approval, which typically involves rigorous clinical trials and regulatory review processes that can extend several years.
ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received the Certificate of Registration from the United States Patent and Trademark Office (USPTO) on Feb 18, 2025, for trademark registration Number 7,692,920, covering the mark "Nutriband™." The Trademark registration covers Goods/Services: Class: 042 Product research and development, scientific research and development; biochemical research and development; pharmaceutical research and development.
The Nutriband™ trademark is integral to the commercialization of the Company’s platform technology AVERSA which can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband’s lead product under development is AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system.
Nutriband, in partnership with Kindeva Drug Delivery, is progressing towards completing the scale-up of the commercial manufacturing process for AVERSA™ Fentanyl, the first product under the AVERSA Platform that the company intends to submit for FDA approval.
According to a market analysis report by Health Advances, AVERSA™ Fentanyl has the potential to reach peak annual U.S. sales of
About AVERSA™ Technology
Nutriband's AVERSA™ abuse deterrent transdermal technology is designed to incorporate aversive agents into transdermal patches, deterring abuse by making the experience unpleasant. This technology is especially significant for drugs like fentanyl, which have a high potential for abuse. AVERSA™ aims to ensure that these essential medications remain accessible to patients who need them while enhancing their safety profiles. The AVERSA™ technology is supported by a robust intellectual property portfolio, with patents granted in the United States and several other countries including Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.
About Nutriband Inc.
Nutriband Inc. is primarily engaged in developing a portfolio of transdermal pharmaceutical products. The Company's lead product in development is an abuse deterrent fentanyl patch that incorporates AVERSA™ technology. This technology can be integrated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites, or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,'' "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2024 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
FAQ
What is the projected market potential for Nutriband's (NTRB) AVERSA Fentanyl?
When did Nutriband (NTRB) receive its USPTO trademark registration?
What does Nutriband's (NTRB) new trademark registration cover?
Who is Nutriband's (NTRB) manufacturing partner for AVERSA Fentanyl?
What is the purpose of Nutriband's (NTRB) AVERSA technology?
